New Strategies in Academic-Industry Collaborations

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Introduction to Academic-Industry Collaborations
• Impact of Bayh-Dole on Technology Transfer to Industry
  • Bayh-Dole and the Rise of Technology Transfer Offices
  • Academia: A Rich Source of Novel Inventions and Innovation for Drug Discovery
  • Challenges in Academic-Industry Relationships
• New Approaches in Academic-Industry Collaborations
  • Collaborative Models
  • Translational Medicine
• Academic and Industry Centers for Drug Discovery.
  • Academic Drug Discovery Centers
  • Pharmaceutical R&D Centers
  • Pharmaceutical R&D Incubators
• Academic-Industry Collaborations of Note
  • Merck/Harvard Medical School
  • GSK/Harvard Stem Cell Institute
  • GSK/Immune Disease Institute
  • AstraZeneca/Columbia University Medical Center
  • Pfizer/ Washington University
  • Pfizer/University of California, San Francisco
  • Janssen Pharmaceutica/Vanderbilt University
  • Centocor/University of Michigan
  • Novartis/MIT
• Outlook for Academic-Industry Collaborations

Tables

• 1. Select Academic Drug Discovery Centers
• 2. Select Pharmaceutical R&D Centers
• 3. Select Academic-Industry Collaborations
• 4. R&D Expenditures of Top Pharmaceutical Companies, 2008

Figures

• 1. Annual National Institutes of Health Budget, 2001-2010
• 2. Staffing of U.S. Technology Transfer Offices, 1998-2007
• 3. Relationships Among Academic Research Institutions and External Entities
• 4. Industrial Research Support for U.S. Universities, Hospitals, and Research Institutions
• 5. Top 20 Academic Biotechnology Patent Filers, 2002-2006